Pieter-jan J. De Kam

Worthing, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based Approach.

The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based Approach.

Journal: Allergy
Published: April 16, 2025

Meta-Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials.

Meta-Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials.

Journal: Allergy
Published: December 24, 2024

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.

Journal: Allergy
Published: September 16, 2024

Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study.

Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study.

Journal: Allergy
Published: August 23, 2024

Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals.

Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals.

Journal: The Journal of allergy and clinical immunology
Published: March 01, 2024

Response to Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy".

Response to Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy".

Journal: Allergy
Published: December 04, 2023

Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy.

Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: July 14, 2023

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.

Journal: Allergy
Published: February 17, 2023

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report.

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report.

Journal: Allergy
Published: March 02, 2021

Dogmas, challenges, and promises in phase III allergen immunotherapy studies.

Dogmas, challenges, and promises in phase III allergen immunotherapy studies.

Journal: The World Allergy Organization journal
Published: January 27, 2021

Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®).

Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®).

Journal: Frontiers in immunology
Published: August 14, 2020

Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing.

Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing.

Journal: The World Allergy Organization journal
Published: February 18, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026